848398-40-3

Usage

Uses

Used in Pharmaceutical Industry:
1H,2H,3H,4H,5H,7H-Furo[3,4-d]pyrimidine-2,4-dione is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential antiviral and anticancer properties. Its unique structure allows for the development of new drugs that can target specific viral and cancer-related pathways, offering novel treatment options for patients.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1H,2H,3H,4H,5H,7H-Furo[3,4-d]pyrimidine-2,4-dione serves as a valuable compound for studying the structure-activity relationships of potential drug candidates. Researchers can use 1H,2H,3H,4H,5H,7H-FURO[3,4-D]PYRIMIDINE-2,4-DIONE to understand how modifications to its structure can influence its biological activity, leading to the discovery of more effective and targeted therapeutic agents.
Used in Drug Development:
1H,2H,3H,4H,5H,7H-Furo[3,4-d]pyrimidine-2,4-dione is utilized in drug development for its potential to be incorporated into new antiviral and anticancer drugs. Its unique molecular features make it an attractive candidate for the creation of innovative medications that can address unmet medical needs and improve patient outcomes.

Upstream product

• 57595-23-0 methyl 4-oxotetrahydrofuran-3-carboxylate 
• 89898-51-1 ethyl tetrahydrofuran-3-one 4-carboxylate 
• 57-13-6 urea 

Downstream Products

• 1542711-45-4 C₁₃H₁₂ClN₃O 
• 1542710-75-7 N-benzyl-2-(2-methyl-2H-indol-1(7aH)-yl)-5,7-dihydrofuro[3,4-d]pyrimidin-4-amine 
• 848398-41-4 2,4-dichloro-5,7-dihydrofuro[3,4-d]pyrimidine 

Relevant academic research and scientific papers

(S)-2-Amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)propanoic Acid (AMPA) and Kainate Receptor Ligands: Further Exploration of Bioisosteric Replacements and Structural and Biological Investigation

Starting from 1-4 and 7 structural templates, analogues based on bioisosteric replacements (5a-c vs 1, 2 and 6 vs 7) were synthesized for completing the SAR analysis. Interesting binding properties at GluA2, GluK1, and GluK3 receptors were discovered. The requirements for GluK3 interaction were elucidated by determining the X-ray structures of the GluK3-LBD with 2 and 5c and by computational studies. Antinociceptive potential was demonstrated for GluK1 partial agonist 3 and antagonist 7 (2 mg/kg ip).

FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX

Fused pyrimidine compounds having a saturated, unsaturated or aromatic A ring fused to a pyrimidine ring and having a complex substituents at the 2 position and a substituted amine at the 4 position of the pyrimidine ring as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine ring and A ring are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity such as cancer.

OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).

CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS

CRF antagonists comprising as an active ingredient, the compound of formula (I) wherein A ring is 5-6 membered mono-cyclic ring which may be substituted; B ring is 5-7 membered unsaturated mono-heterocyclic ring which may be contained another 1-2 of hetero atom(s) and substituted by another substituents; W1 and W2 is carbon atom or nitrogen atom; Z is NR3, oxygen atom, sulfur which may be oxidized or CR4R5; R' is alkyl, alkenyl or alkynyl that may be substituted, amino which may be protected, hydroxyl which may be protected, S(O)nR6, COR7, or cyclic group which may be substituted; R2 is unsaturated cyclic group which may be substituted.